対象症例を①新規 RA 群：初診時または 2 回目の受診時に RA と診断のついた群、②Pre-RA 群：関節リウマチに進展しうる関節症状を有する群、③Non-RA 群：無症候群で半年ごとの定期外来受診の対象となった群に分類し、各群の最終受診時の臨床所見、検査所見より RA の診断の有無を判定した。

RA の診断は 2010 ACR/EULAR RA classification criteria に従った。

（倫理面への配慮）

本研究は鳥取大学医学部倫理審査の承認を得て実施した（No2648）。



図１．対象患者の選択とフォロー

C．研究結果

１．抗 CCP 抗体検査

772 例に対し 1058 回の抗 CCP 抗体検査が実施されていた．このうち、185 例で 552 回の検査が実施され RA の確定診断が下されていた。初回検査後のフォローアップのなかった 188 例 188 検査を除いた 249 例 318 検査をフォローアップ解析対象とした。これらは新規 RA 群に 53 例が、Pre-RA 群に 25 例が、Non-RA 群に 171 例が分類された。

２．抗 CCP 抗体による診断率

新規 RA 群においては 53 例中 32 例(60.4%)が抗 CCP 抗体陽性であり、とくに 29 例(54.7%)は高力価陽性であった（表１）。



図２．　検討対象患者



図３．抗 CCP 抗体検査実施例の推移

Pre-RA 群においては 25 例中 4 例(16.0%)が抗 CCP 抗体陽性であり、うち 2 例はその後の経過観察中に RA と確定診断された。

Non-RA 群においては 171 例中 5 例(2.9%)のみ抗 CCP 抗体陽性であったが、その後の経過観察で RA と診断された例はなかった。また Non-RA 群で抗 CCP 抗体が陰性であった 166 例(97.1%)中、後に RA と診断されたのは 1 例のみであった。

表１．各群の ACPA 陽性率

	RA群 (n=53)	Pre-RA群 (n=25)	Non-RA群 (n=171)
陽性例	32	4	5
高力価陽性例	29	4	1
陽性率	60.4%	16.0%	2.9%



図４．Pre-RA群の経過



図５．Non-RA 群の経過

D．考察

新規 RA 群において高率に抗 CCP 抗体が陽性であったこと、Pre-RA 群において抗 CCP 抗体陽性例の半数がのちに RA へと進展したことから、抗 CCP 抗体によるスクリーニングは RA の早期発見に有用と思われた．一方、このスクリーニングによって患者予後が向上するか否かについては、より長期間の経過観察が必要である。

また Non-RA 群においては、抗 CCP 抗体が陽性であっても RA へと進展した例は現時点ではなかったが、今後 RA を発症する可能性も考えられ、無症状の抗 CCP 抗体陽性者をフォローアップすることで RA を早期発見できるかについては、より長期のフォローアップを待って判断したい．他方、Non-RA 群における抗 CCP 抗体の陰性的中率は 99.4%と極めて優れており、この点からも抗 CCP 抗体のスクリーニング検査としての有用性が示されたといえる。

E．結論

抗 CCP 抗体検査は、RA のスクリーニング検査として有用である。

F．研究発表

1. 論文発表

1) Hagino H, Takano T, Fukunaga M, et al.,Elde calcitol reduces the risk of severe vertebral fr actures and improves the health-related quality of life in patients with osteoporosis,J Bone Miner Metab,31,2 ,183,189,2013

2) Sakamoto K, Endo N, Harada A, Sakada T, Tsushita K, Kita K, Hagino H, et al.,Why not use your own body weight to prevent falls? A randomized, controlled trial of balance ther apy to prevent falls and fractures for elderly people who can stand on one leg for </=15 s.,J Orthop Sci,18,,110,120,2013

3) Nagira K, Hagino H, Kameyama Y, Teshima R, Effects of minodronate on cortical bone re sponse to mechanical loading in rats, Bone,53,, 277,283,2013

4) Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, et al.,Ver tebral Fracture Risk after Once-Weekly Teripa ratide Injection - Follow-up Study of Teriparat ide Once-Weekly Efficacy Research (TOWER) Trial,Curr Med Res Opin,29,3 ,195,203,2013

5) Dokai T,Nagashima H,Okano T,Nanjo Y, Kish imoto Y,Tandai A,Kakite S, Hagino H, Morp

hological and Volumetric Analysis of the Development of Vertical Subluxation in Rheumatoid Arthritis, Yonago Acta Medica,56,,21,27,2013

6) Tanida A,Kishimoto Y,Okano T,Hagino H, Etanercept promotes bone formation via suppression of Dickkopf-1 expression in rats with collagen-induced arthritis ,Yonago Acta Medica,56,,13,19,2013

7) Hagino H, Kishimoto H, Ohishi H, et al., Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5mg once-daily dosage regimen,Bone,59C,44,52,2013

8) Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, et al., Diagnostic criteria for primary osteoporosis: year 2012 revision,J Bone Miner Metab,31,3,247,257,2013

9) Sota T, Matsuo S, Uchida Y, Hagino H, Kawai Y,Effects of lower body positive pressure on cardiovascular responses during walking in elderly women,Physiol Res,62,6 ,653,662,2013

10) Mori S, Soen S, Hagino H, et al., Justification criteria for vertebral fractures: year 2012 revision,J Bone Miner Metab,31,3 ,258,261,2013

11) Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M, Takada J, Chaki O, Hagino H, et al., Guidelines for the use of bone turnover markers in the Diagnosis and Treatment of Osteoporosis (2012 Edition),J Bone Miner Metab,31,1 ,1,15,2013

12) Hagino H, ELDECALCITOL – Newly developed active vitamin D3 analog for the treatment of osteoporosis,Expert Opinion On Pharmacotherapy,14,6 ,817,825,2013

13) Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, et al., Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03),J Bone Miner Metab,32,3 , 298,304,2014

14) Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, et al., Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial,J Bone Miner Metab,32,4 ,441,446,2014

15) Tokuda T, Hasegawa J, Matsuda A, Hagino H, Bone mineral density in residents of care facilities for the aged and effect of pharmacotherapy,Yonago Acta Medica,57,,45,52,2014

16) Hagino H, Other non-vertebral fractures,Best Practice & Research Clinical Rheumatology,27,731,741,2014

17) Matsumoto H, Makabe T, Morita T, Ikuhara K, Kajigase A, Okamoto Y, Ashikawa E, Kobayashi E, Hagino H, Accelerometry-based gait analysis predicts falls among patients with a recent fracture who are ambulatory, Int J Rehabil Res (in press)

18) Matsumoto H, Okuno M, Nakamura T, Yama

moto K, Osaki M, Hagino H, Incidence and risk factors for falling in patients after total knee arthroplasty compared to healthy elderly individuals, Yonago Acta Medica, 57, 137, 145, 2014

19) Hagino H, Yoshida S, Hashimoto J, Matsunaga M, Tobinai M, Nakamura T, Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study, Calcif Tissue Int , 95, 557, 563, 2014

2. 学会発表

1) 岸本勇二、岡野　徹、萩野　浩、豊島良太, 関節リウマチにおける大関節炎の存在は身体機能の予後不良因子である, 第86回日本整形外科学会学術総会、広島、2013

2) 岸本勇二、林原雅子、萩野　浩, 長期罹患関節リウマチ症例に対するtight controlの有効性と限界, 第58回日本リウマチ学会学術総会、東京、2014

3) Hagino H, Japanese experiences in the use of bisphosphonates, 2nd Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research, 2013.5.21-6.1, 神戸

4) Hagino H, Fragility Fracture Prevention by Bisphosphonate from a Japanese Perspective, 2nd Joint Meeting of the International Bone and Mineral Society and the Japanese Society for Bone and Mineral Research, 2013.5.21-6.1, 神戸

5) Hagino H, The Epidemiological Challenge of Fragility Fractures in SE Asia Region, Fragility Fracture Network Meeting Korea 2013, 2013.6.23, Seoul

6) Hagino H, Nakamura T, Ito M, Nakano T, Hashimoto J, Tobinai M, Mizunuma H, Bone Mineral Density Increases with Monthly i.v. Ibandronate Injections Contribute to its Fracture Risk Reduction in Primary Osteoporosis: 3-Year Analysis of the Phase III MOVER Study, ASBMR 2013, 2013.10.4-7, Baltimore

7) Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T, The instructive effects of minodronate on prevention of new vertebral fractures at the higher fracture risk of Japanese patients with osteoporosis, ASBMR 2013, 2013.10.4-7, Baltimore

8) 萩野　浩, 骨粗鬆症の新たな治療戦略–ビスホスホネート注射剤は何を変えるか？-, 第28回日本臨床リウマチ学会, H25.11.30-12.1, 千葉

9) Hagino H, Nakamura T, Minamizaki T, Tsuda K, Morio Y, EFFECT OF CALCITONIN ON POSTOPERATIVE PARAMETERS IN PATIENTS WITH HIP FRACTURES – FOCUS ON THE PATIENTS' ADL AND QOL, 4th Asia-Pacific Osteoporosis Meeting , 2013.12.12-15, HongKong

10) Hagino H, Nakamura T, Ito M, Nakano T, Hashimoto J, Tobinai M, Mizunuma H, BONE MINERAL DENSITY INCREASES WITH MONTHLY I.V. IBANDRONATE INJECTIONS CONTRIBUTE TO ITS FRACTURE RISK REDUCTION IN PRIMARY OSTEOPOROSI

S: 3-YEAR ANALYSIS OF THE PHASE III MOVER STUDY, 4th Asia-Pacific Osteoporosis Meeting , 2013.12.12-15, HongKong

11) Hagino H, Fragility Fracture Prevention - Japanese Experience and Perspectives, 4th Asia-Pacific Osteoporosis Meeting , 2013.12.12-15, HongKong

12) Hagino H, The Light and Shadow of Bisphosphonate Treatment - a Japanese Perspective, the Annual Meeting of the Korean Society of Osteoporosis 2014, 2014.4.6, Seoul

13) 萩野　浩, 骨粗鬆症における骨折連鎖の予防, 第58回日本リウマチ学会総会・学術集会, 2014.4.24-26, 東京

14) Hagino H, Current issues in prevention of fragility fracture in Japan, 11th Meeting of Bone Biology Forum, 2014.8.22-23, 裾野市

15) Hagino H, Fracture risk and secondary prevention following fragility fracture, 2nd Asia-Pacific Bone & Mineral Research Meeting, 2014.5.30-6.1, Seoul

16) Hagino H, Nakamura T, Ito M, Nakano T, Hashimoto J, Tobinai M, Mizunuma H, The effect of monthly i.v. ibandronate injections on Japanese patients with high-risk primary osteoporosis:subgroup analysis of the phase III MOVER study, ASBMR 2014, ,

17) Hagino H, Fracture Liaison Services in Asia Pacific, IOF Regionals in Taipei 2014, 2014.11.14-16, 台北

18) Hagino H, Nakamura T, Ito M, Nakano T, Hashimoto J, Tobinai M, Mizunuma H, The effect of monthly i.v. ibandronate injections on Japanese patients with high-risk primary osteoporosis: subgroup analysis of the Phase III MOVER study, IOF Regionals in Taipei 2014, 2014.11.14-16, 台北

19) Hagino H, Sugimoto T Soen S, Endo N, Okazaki R, Tanaka K, Nakamura T, Study on Factors for Osteoporosis Quality-Of-life in Japanese Subjects, IOF Regionals in Taipei 2014, 2014.11.14-16, 台北

G．知的財産権の出願・登録状況

（予定を含む．）

1. 特許取得

な　し

2. 実用新案登録

な　し

3. その他

な　し

厚生労働科学研究費補助金
（難治性疾患等克服研究事業（難治性疾患等実用化研究事業
（免疫アレルギー疾患等実用化等研究事業　免疫アレルギー疾患実用化研究分野））
分担研究報告書

危険因子を同定する検診制度導入によるリウマチ制圧プロジェクト（三重地区）

研究分担者　若林 弘樹　三重大学医学部附属病院　整形外科　講師
研究協力者　須藤 啓広　三重大学医学部附属病院　整形外科　教授

研究要旨：抗体スクリーニング検査による関節リウマチ(RA)患者の早期発見の有無、および抗体陽性者の予後向上の有無の検討が本研究の目的である。三重県内の自治体および当科における健康診断にて、抗CCP抗体および/またはリウマトイド因子検査を行い、陽性者には専門機関への受診を勧める。定期的フォローアップを原則として行い、その後のRA発症の有無を追跡し、早期診断・早期治療に務め、抗体スクリーニング検査の有用性および抗体陽性者の予後向上の有無について検討する。

A. 研究目的

抗体スクリーニング検査による関節リウマチ(RA)患者の早期発見の有無、および抗体陽性者の予後向上の有無の検討。

B. 研究方法

平成 25 年度旧宮川村運動器検診受診、および平成 25-26 年度志摩市 20 歳の健診受診で希望者に抗 CCP 抗体およびリウマトイド因子(RF)を追加で測定した。

（倫理面への配慮）

インフォームドコンセントを徹底し、対象者・対象機関が同定されないようにする必要がある場合は、匿名化により対応した。調査にあたり、「臨床研究に関する倫理指針」を遵守した。

C. 研究結果

運動器検診受診者 220 人中(平均年齢 74.4 歳：高齢コホート)、抗 CCP 抗体陽性者は 2 人、RF 陽性者は14人であった。20歳の健診受診者は303人中（平均年齢 25.6 歳：成人コホート)、抗 CCP 抗体陽性者は 1 人、RF 陽性者は 7 人であった。

D. 考察

スクリーニングによる抗 CCP 抗体陽性者は高齢コホート 0.9%、成人コホート 0.3%であり、Fisher 検定では有意な発現の差はみられなかった。RF に関しては高齢コホート 6.9%、成人コホート 2.3%であり、有意に高齢群の方が陽性率が高く($p<0.05$)、これまでの報告と同様の傾向がみられた。抗 CCP 抗体および RF 陽性者の follow による早期診断および予後向上の有無について調査していく予定である。本研究は「危険因子を同定する検診制度導入によるリウマチ制圧プロジェクト」の分担研究であり、三重地区のデータとして収集される。

E. 結論

抗体スクリーニング検査により抗 CCP 抗体陽性者は 0.3-0.9%、RF 陽性者は 2.3-6.9%%であった。抗 CCP 抗体の陽性率は今回の検討では年齢による発現差はみられなかった。

F. 研究発表

1. 論文発表
   なし
2. 学会発表
   なし

G. 知的所有権の取得状況

該当なし

Ⅲ．　研究成果の刊行に関する一覧

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
なし							

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.	Mod Rheumatol.	24(1)	26-32	2014
Kadoya M, Yamamoto A, Hamaguchi M, Obayashi H, Mizushima K, Ohta M, Seno T, Oda R, Fujiwara H, Kohno M, Kawahito Y.	Allograft inflammatory factor-1 stimulates chemokine production and induces chemotaxis in human peripheral blood mononuclear cells.	Biochem Biophys Res Commun.	448(3): doi: 10.1016/j.bbrc.2014.04.106.	287-91.	2014
Fujioka K, Kishida T, Ejima A, Yamamoto K, Fujii W, Murakami K, Seno T, Yamamoto A, Kohno M, Oda R, Yamamoto T, Fujiwara H, Kawahito Y, Mazda O.	Inhibition of osteoclastogenesis by osteoblast-like cells genetically engineered to produce interleukin-10.	Biochem Biophys Res Commun.	456(3): doi: 10.1016/j.bbrc.2014.12.040.	785-91.	2015
Taniguchi D[1], Tokunaga D, Oda R, Fujiwara H, Ikeda T, Ikoma K, Kishida A, Yamasaki T, Kawahito Y, Seno T, Ito H, Kubo T.	Maximum intensity projection with magnetic resonance imaging for evaluating synovitis of the hand in rheumatoid arthritis: comparison with clinical and ultrasound findings.	Clin Rheumatol.	33(7): doi: 10.1007/s10067-014-2526-1.	911-7.	2014

Ⅳ.　研究成果の刊行物・別刷

Japan College of Rheumatology
MODERN RHEUMATOLOGY

http://informahealthcare.com/mor
ISSN 1439-7595 (print), 1439-7609 (online)

Mod Rheumatol, 2014; 24(1): 26–32
© 2013 Japan College of Rheumatology
DOI 10.3109/14397595.2013.854080

informa
healthcare

ORIGINAL ARTICLE

Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study

Norihiro Nishimoto · Koichi Amano · Yasuhiko Hirabayashi · Takahiko Horiuchi · Tomonori Ishii · Mitsuhiro Iwahashi · Masahiro Iwamoto · Hitoshi Kohsaka · Masakazu Kondo · Tsukasa Matsubara · Toshihide Mimura · Hisaaki Miyahara · Shuji Ohta · Yukihiko Saeki · Kazuyoshi Saito · Hajime Sano · Kiyoshi Takasugi · Tsutomu Takeuchi · Shigeto Tohma · Tomomi Tsuru · Yukitaka Ueki · Jiro Yamana · Jun Hashimoto · Takaji Matsutani · Miho Murakami · Nobuhiro Takagi

Received: 27 September 2011 / Accepted: 15 April 2013

Abstract

Objectives To evaluate the safety and efficacy of retreatment with tocilizumab (TCZ) in patients who had participated in the DREAM study (*Drug free* remission/low disease activity after cessation of tocilizumab [Actemar] monotherapy study) and had experienced loss of efficacy.

Methods Patients were retreated with TCZ or other disease modifying antirheumatic drugs (DMARDs). Disease activity was measured using the 28-joint disease activity score (DAS28) for 12 weeks.

Results A total of 164 eligible patients, including 161 who experienced loss of efficacy within 52 weeks of the DREAM study, resumed treatment: 157 with TCZ and 7 with DMARDs and/or infliximab. Of TCZ-treated patients, 88.5 % (139 patients) achieved DAS28 <2.6 within 12 weeks, whereas among patients treated with DMARDs and/or infliximab only 14.3 % (1 patient) achieved DAS28 <2.6. Adverse events were observed in 70 TCZ-treated patients (44.0 %), but no serious infusion reactions were observed.

Conclusions Retreatment with TCZ was well-tolerated and effective in patients who had responded to the preceding TCZ monotherapy but had experienced loss of efficacy after cessation of TCZ.

Keywords Interleukin 6 · Retreatment · *Drug free* · Rheumatoid arthritis · Tocilizumab

For the MRA study group for RA.

N. Nishimoto (✉)
Osaka Rheumatology Clinic, Tatsuno-Sinsaibashi-Building 5th Floor, 4-4-10 Minamisenba Chuo-ku, Osaka 542-0081, Japan
e-mail: norichan@wakayama-med.ac.jp; nishimot@tokyo-med.ac.jp

N. Nishimoto · M. Murakami
Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan

N. Nishimoto · T. Matsutani · M. Murakami
Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan

K. Amano
Department of Rheumatology/Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan

Y. Hirabayashi
Department of Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan

T. Horiuchi
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

T. Ishii
Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Miyagi, Japan

M. Iwahashi · J. Yamana
Higashihiroshima Memorial Hospital, Higashihiroshima, Japan

M. Iwamoto
Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan

H. Kohsaka
Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan

M. Kondo
Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan

Published online: 17 May 2013

Introduction

Tocilizumab (TCZ) treatment frequently achieves remission in patients with rheumatoid arthritis (RA) as measured by the 28-joint disease activity score (DAS28) [1–12]. We have demonstrated in the DREAM study (*Drug free* remission/low disease activity (LDA) after cessation of TCZ [Actemra] monotherapy study) [13] that in some cases the efficacy of TCZ is sustained for more than 1 year after cessation of TCZ and without the use of other disease modifying antirheumatic drugs (DMARDs). However, the majority of patients experienced loss of efficacy, and needed to restart treatment for RA. In this study we evaluate the safety and efficacy of TCZ retreatment at recurrence of disease activity after cessation of TCZ.

Methods

Patients

All patients who participated in the DREAM study and had experienced loss of efficacy were enrolled. Criteria for loss of efficacy in the DREAM study was defined as DAS28-erythrocyte sedimentation rate (ESR) >3.2 at 2 consecutive observations, initiation of additional RA treatments including increase in oral corticosteroid dose, the patient's request for retreatment, or the treating physician judging that retreatment was necessary.

Study protocol

The study protocol was approved by the Ministry of Health, Labour and Welfare of Japan and by the local ethical committees. This study is registered with http://clinicaltrials.gov (NCT00661284). Patients were treated with biologic DMARDs including TCZ and infliximab (IFX), and/or conventional synthetic DMARDs including methotrexate (MTX). If the patient received TCZ retreatment, TCZ was administered intravenously (8 mg/kg) every 4 weeks. Other biologic DMARDs and/or synthetic DMARDs were administered based on the dosage and regimen in the package insert. The concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs was allowed during the study period.

Anti-tocilizumab antibodies

Serum anti-TCZ antibody levels were determined by ELISA. Serum was added to the wells coated with 100 μl of Fab fragment of TCZ (0.2 μg/ml) and incubated for 2 h. After washing, biotin-conjugated TCZ was added and developed with alkaline phosphatase conjugated to streptavidin.

IgE-type anti-TCZ antibodies were also measured by ELISA. In this case, whole TCZ was used because an antigen coated each cup, and enzyme-linked anti-IgE antibodies were used as second antibodies.

T. Matsubara
Matsubara Mayflower Hospital, Hyogo, Japan

T. Mimura
Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan

H. Miyahara
National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

S. Ohta
Department of Rheumatology, Taga General Hospital, Ibaraki, Japan

Y. Saeki · J. Hashimoto
National Hospital Organization Osaka-Minami Medical Center, Osaka, Japan

K. Saito
The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan

H. Sano
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

K. Takasugi
Dohgo Spa Hospital, Ehime, Japan

T. Takeuchi
Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan

S. Tohma
Sagamihara National Hospital, National Hospital Organization, Kanagawa, Japan

T. Tsuru
PS Clinic, Fukuoka, Japan

Y. Ueki
Sasebo Chuo Hospital, Nagasaki, Japan

N. Takagi
Chugai Pharmaceutical Co. Ltd., Tokyo, Japan

Statistical analysis

Clinical response was measured by DAS28-ESR. Remission was defined, in accordance with the European League Against Rheumatism (EULAR) definition, as DAS28 <2.6 [14]. The rates of remission under the new EULAR/American College of Rheumatology (ACR) remission criteria (Boolean definition) were also considered [15]. Adverse events (AEs) and serious adverse events (SAEs) were tabulated after converting the verbatim event names to MedDRA Ver. 8.0 System Organ Class (SOC) terms.

The factors contributing to the resumption of DAS28-ESR remission after retreatment were estimated from univariate and multivariate logistic regression analyses using the following patient baseline data for this study: DAS28-ESR, tender joint count (TJC), swollen joint count (SJC), patient's global assessment (Pt-GA), modified health assessment questionnaire (MHAQ) score, serum C-reactive protein (CRP) concentration, erythrocyte sedimentation rate (ESR), serum IL-6 concentration, serum matrix metalloproteinase (MMP)-3 concentration, and the duration of TCZ cessation. In the multivariate logistic analysis, stepwise selection with a level of significance of 0.05 was used for entry or removal of variables. Logistic regression analysis was also conducted to analyse the relationship between the TCZ treatment interval and development of AEs during this study.

Results

Characteristics of patients

In total, 166 patients were enrolled and resumed treatments. Of the patients who received TCZ retreatment, 2 were ineligible and were excluded from the analysis of efficacy. The 164 remaining patients eligible for analysis of efficacy included 161 patients who had experienced loss of efficacy by week 52 of the DREAM study, and 3 patients who had experienced loss of efficacy after completion of the DREAM study (an interval of >1 year).

In the 164 eligible patients, 73 patients (44.5 %) resumed treatment due to DAS28-ESR >3.2 at 2 consecutive visits, 66 patients (40.2 %) to investigator's judgement, 11 patients (6.7 %) to patients' request, and 14 patients (8.5 %) to addition of RA treatments including increase in oral corticosteroid dose. The major reason investigators judged retreatment was necessary was a DAS28-ESR >3.2 score at one visit in 55/66 patients (83.3 %). Four out of eleven patients who requested treatment were also DAS28-ESR >3.2. Therefore, 146/164 patients were DAS28-ESR >3.2 at the baseline of the RESTORE study (the mean DAS28-ESR[95 %CI] was 4.6 [4.5–4.8]).

A total of 159 patients received at least 1 infusion of TCZ (including 2 ineligible patients), and 7 patients received other DMARDs, including MTX, tacrolimus, and/or IFX. In the TCZ-treated patients, 133 patients received TCZ monotherapy and 26 received TCZ therapy in combination with synthetic DMARDs (25 patients with MTX; 1 patient with salazosulfapyridine). The median treatment interval between the last TCZ infusion and restarting the TCZ treatment in this study was 13.1 weeks (min–max, 6.14–60.4 weeks). Corticosteroids were used concomitantly in 57 of the patients treated with TCZ and in 4 of the patients treated with other DMARDs. The median corticosteroid dose in TCZ-treated patients at baseline of this RESTORE study was 3.0 mg/day, which was comparable with the median dose in patients treated with other DMARDs (2.3 mg/day). Other baseline characteristics of the patients who received TCZ were comparable with those of patients treated with other DMARDs (Table 1).

Efficacy of TCZ retreatment

The mean (±SD) DAS28-ESR before initial treatment using TCZ in the previous clinical studies (i.e. Japanese phase I/II open-label dose escalation study, a phase II double-blind dose finding study, a phase III open-label randomized study (SAMURAI), a phase III double-blind study (SATORI), a drug–drug interaction study, and a renal failure study) was 6.2 (±1.0) and improved with 12 weeks of TCZ treatment to 2.8 (±1.2). The mean (±SD) DAS28-ESR at the last observation point of the previous TCZ treatment studies (i.e., baseline of the DREAM study) was 1.5 (±0.7) (Fig. 1a).

In this study, the mean (±SD) DAS28-ESR in patients who restarted TCZ treatment decreased from 4.4 (±1.1) (95 % CI: 4.2–4.6) before restarting treatment to 1.8 (±0.8) (95 % CI: 1.6–1.9) after 12 weeks of treatment. In contrast, the mean (±SD) DAS28-ESR in patients treated with DMARDs and/or IFX was 4.2 (±1.1) (95 % CI: 3.2–5.2) before restarting treatment and 3.3 (±1.0) (95 % CI: 2.5–4.2) after 12 weeks of treatment (Fig. 1a).

Of the TCZ-retreated patients, 95.5 % (150/157 patients, 95 % CI: 91.0–98.2 %) achieved DAS28-ESR ≤3.2 and 88.5 % (139/157 patients, 95 % CI: 82.5–93.1 %) achieved DAS28-ESR <2.6 within 12 weeks as compared to only 28.6 % of the other DMARD-treated patients (2/7 patients, 95 % CI 3.7–71.0 %) achieving DAS28-ESR ≤3.2 and 14.3 % (1/7 patients, 95 % CI: 0.4–57.9 %) achieving DAS28-ESR <2.6.

The percentage of TCZ-retreated patients who reached DAS28-ESR <2.6 within 12 weeks in the TCZ monotherapy group (87.9 %, 116/132 patients, 95 % CI: 81.1–92.9 %) was comparable to the percentage in the TCZ plus synthetic DMARDs therapy group (92.0 %, 23/25 patients, 95 % CI: 74.0–99.0 %).

Table 1 Demographic and clinical characteristics of patients at baseline of RESTORE study

No. of patients	Total	Patients treated with TCZ	Patients treated with other DMARDs
	166	159[a]	7
Age, years (median [range])	57 (26–78)	56 (26–78)	65 (42–74)
Gender, female (%)	149 (89.8)	144 (90.6)	5 (71.4)
Disease duration, years (median [range])	7.8 (3.7–24.0)	7.7 (3.7–24.0)	8.6 (6.9–18.9)
No. (%) of patients using concomitant corticosteroids	61 (36.7)	57 (35.8)	4 (57.1)
Dose, mg/day (prednisolone equivalent) (median [range])	3.0 (0.5–10.0)	3.0 (0.5–10.0)	2.3 (2.0–7.0)
DAS28-ESR (median [range])	4.3 (0.8–7.8)	4.4 (0.8–7.8)	4.1 (2.9–5.9)
(Mean ± SD)	4.4 ± 1.1	4.4 ± 1.1	4.2 ± 1.1
Tender joint count (28-joint count) (median [range])	3.0 (0–27)	3.0 (0–27)	3.0 (1–5)
(Mean ± SD)	4.3 ± 4.3	4.4 ± 4.4	2.6 ± 1.4
Swollen joint count (28-joint count) (median [range])	2.0 (0–16)	2.0 (0–16)	2.0 (0–7)
(Mean ± SD)	3.3 ± 3.1	3.3 ± 3.2	2.4 ± 2.2
CRP, mg/dl (median [range])	0.8 (0.0–13.5)	0.9 (0.0–13.5)	0.8 (0.1–4.7)
(Mean ± SD)	1.6 ± 2.1	1.6 ± 2.1	1.2 ± 1.6
ESR, mm/h (median [range])	36 (2–115)	37 (2–115)	32 (16–113)
(Mean ± SD)	41 ± 24	40 ± 23	49 ± 39
MHAQ score (median [range])	0.3 (0.0–2.1)	0.4 (0.0–2.1)	0.0 (0.0–0.8)
(Mean ± SD)	0.5 ± 0.5	0.5 ± 0.5	0.2 ± 0.3
MMP-3, ng/ml (median [range])	95 (34–800)	96 (34–800)	77 (44–319)
(Mean ± SD)	167 ± 167	169 ± 169	129 ± 112

DAS28 28-joint disease activity score, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *MHAQ* modified health assessment questionnaire, *MMP-3* matrix metalloproteinase-3, *TCZ* tocilizumab, *DMARDs* disease modifying antirheumatic drugs

[a] Two ineligible patients who did not meet the eligible criteria of DREAM study were included

The mean (±SD) tender joint count (TJC) in 28 joints in TCZ-retreated patients improved from 4.4 (±4.4) before restarting treatment to 0.8 (±1.6) after 12 weeks. The mean (±SD) swollen joint count (SJC) in 28 joints also improved from 3.3 (±3.2) to 0.8 (±1.6) (Fig. 1b). Moreover, 63.1 % of patients (99/157) had no tender and/or swollen joints after 12 weeks retreatment with TCZ (Fig. 1c). Under the Boolean remission criteria, the remission rate by TCZ treatment was 43.9 % (69/157 patients, 95 % CI: 36.0–52.1 %) at week 12 (Fig. 1d). The mean (±SD) MMP-3 values in TCZ-retreated patients improved from 166.5 (±164.5) ng/ml at baseline in this study, i.e. prior to TCZ retreatment, to 77.4 (±64.8) ng/ml at week 12. Univariate logistic regression analysis showed the following variables to be associated with the resumption of DAS28-ESR remission: lower DAS28-ESR, lower TJC, lower SJC and lower MHAQ at baseline. On the other hand, duration of TCZ cessation in the DREAM study was not associated with resumption of DAS28-ESR remission (Fig. 2). Multivariate logistic regression analysis showed that lower DAS28-ESR at baseline was the contribution factor for resumption efficacy.

At baseline, 17 patients had DAS28-ESR ≤3.2. Thus, we further analysed efficacy in the 140 patients who had DAS28-ESR >3.2 at the baseline (the mean DAS28-ESR [95 % CI] was 4.6 [4.5–4.8]) and restarted TCZ in this study. Out of these patients, 87.1 % (122/140 patients, 95 % CI: 80.4–92.2 %) achieved DAS28-ESR <2.6 and 42.9 % (60/140 patients, 95 % CI: 34.5–51.5 %) achieved Boolean remission within 12 weeks. In addition, univariate and multivariate logistic regression analysis also identified lower DAS28-ESR value at baseline to be the factor contributing the resumption of DAS28-ESR remission by 12 weeks of TCZ treatment in these patients. These results are not significantly different from those including the patients with DAS28-ESR ≤ 3.2 at baseline.

Safety of TCZ retreatment

AEs were reported in 44.0 % (70/159) of the patients who were retreated with TCZ and in 42.9 % (3/7) of the patients treated with other DMARDs. All AEs reported in the TCZ-treated group were mild and tolerable relative to the benefit provided. The incidence rate of AEs in the TCZ monotherapy group (42.9 %, 57/133 patients, 95 % CI: 34.3–51.7) was comparable to the incidence rate in the TCZ plus synthetic DMARDs therapy group (50.0 %, 13/26 patients, 95 % CI: 29.9–70.1). There was no



Fig. 1 Changes in DAS28-ESR, tender joint count, swollen joint count, and Boolean remission rate after resumption of treatment. **a** Mean (±SD) change in DAS28-ESR: from baseline of the initial tocilizumab (TCZ) treatment to week 12 and last observation point of the long-term extension studies (*closed circles*), and from the baseline of this study to week 12 in patients retreated with TCZ (*closed squares*) and in patients treated with other DMARDs (*open circles*). *Error bars* show SD. **b** Mean (+SD) tender joint count in 28 joints (*closed circles*), and mean (+SD) swollen joint count in 28 joints in TCZ-retreated patients (*open circles*). *Error bars* show SD. **c** Proportion of TCZ-retreated patients with no tender joints (*solid bars*) and those with no swollen joints (*open bars*). **d** Remission rates under the new EULAR/ACR remission criteria in the TCZ-retreated patients. *TJC* tender joint count, *SJC* swollen joint count, *LO* last observation point



Fig. 2 Factors associated with resumption of DAS28-ESR remission by 12 weeks of TCZ retreatment after cessation of TCZ therapy. Factors contributing to the resumption of DAS28-ESR remission by 12 weeks of TCZ treatment were estimated by univariate and multivariate logistic regression analyses. *OR* odds ratio, *CI* confidence interval, *DAS28* 28-joint disease activity score, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *MHAQ* modified health assessment questionnaire, *IL-6* interleukin 6, *MMP-3* matrix metalloproteinase 3, *TCZ* tocilizumab

relationship between the development of AEs and the duration of TCZ cessation in the DREAM study. Infections were the most common AEs in the TCZ-treated group (27 patients, 17.0 %) (Table 2). None of the patients in this study were positive for anti-TCZ IgE antibodies. Only 1 patient who discontinued TCZ treatment for 35 weeks

Table 2 Adverse events observed after restarting TCZ treatment

Adverse event (SOC)	No. patients (%)
Total	70 (44.0)
Infections and infestations	27 (17.0)
Investigations	17 (10.7)
Gastrointestinal disorders	14 (8.8)
Skin and subcutaneous tissue disorders	12 (7.5)
Injury, poisoning and procedural complications	8 (5.0)
Respiratory, thoracic and mediastinal disorders	5 (3.1)
Nervous system disorders	3 (1.9)
General disorders and administration site conditions	3 (1.9)
Neoplasms benign, malignant and unspecified	2 (1.3)
Eye disorders	2 (1.3)
Vascular disorders	2 (1.3)
Musculoskeletal and connective tissue disorders	2 (1.3)
Blood and lymphatic system disorders	1 (0.6)
Immune system disorders	1 (0.6)
Ear and labyrinth disorders	1 (0.6)
Cardiac disorders	1 (0.6)
Reproductive system and breast disorders	1 (0.6)

SOC MedDRA Ver. 8.0 System Organ Class

became positive for anti-TCZ IgG antibodies 12 weeks after restarting TCZ treatment, and no decrease in the efficacy or any infusion reaction was observed in this patient. Moreover, no serious allergic reactions were reported in any patient.

One patient who discontinued TCZ treatment for 24 weeks experienced an infusion reaction 8 weeks after restarting TCZ therapy. The reactions included eruption, fatigue, and hypertension following the third infusion, but were mild and transient and did not require any treatment.

Three SAEs (1.9 %) were reported during retreatment with TCZ: appendicitis, wrist fracture, and chronic sinusitis. Causal relationships with TCZ were ruled out in the wrist fracture and chronic sinusitis.

Discussion

This study demonstrated that retreatment with TCZ was well-tolerated and effective in patients who had previously withdrawn from TCZ treatment. None of the patients in this study developed anti-TCZ IgE antibodies and only 1 patient tested positive for anti-TCZ IgG antibodies after restarting the TCZ treatment. Moreover, no serious allergic reactions were reported in any patient, including 3 patients retreated with TCZ after a long-term interval of more than 1 year. Our results confirm the results reported by Sagawa [16]. On the other hand, the development of serious infusion reactions was reported in patients who had restarted IFX treatment after long-term cessation of IFX [17]. This difference between TCZ and IFX can be attributable to the fact that, whereas IFX is a chimeric monoclonal antibody, TCZ is humanised, which reduces the content of foreign protein and thus the potential for the development of neutralising antibodies or IgE antibodies.

Regarding the efficacy of restarting TCZ at recurrence of disease activity after the cessation of TCZ treatment, the DAS28-ESR remission rate at 12 weeks after restarting TCZ was 88.5 %, which is comparable to the remission rate at the last observation point before cessation of initial TCZ treatment in the DREAM study (90.4 %). This improvement in DAS28-ESR was induced not only by improvement in acute-phase reactions, but also by improvement in TJC and SJC: over 60 % of the TCZ-retreated patients had complete improvement in terms of TJC or SJC or both (TJC or SJC or both was zero) within 12 weeks of treatment. Moreover, the Boolean remission rate as newly recommended by ACR/EULAR [15] reached 43.9 % (69/157 patients) at week 12. This value was extremely high.

The ACR/EULAR treatment recommendations state that, in patients who achieve remission with biological products, it may be possible to taper off the biological product after tapering off the corticosteroid [18]. However, in the majority of patients who discontinue treatment with biologics, it is found that efficacy cannot be sustained without use of the biologics and that disease activity may increase [16, 19]. This fact indicates that after attempting discontinuation of treatment with a biologic DMARD, it is necessary to guarantee safety and the ability to resume efficacy when restarting treatment with the same DMARD. Our results clearly indicate that TCZ was well-tolerated and effective in the patients who resumed TCZ treatment.

MMP-3 is deeply involved in cartilage destruction in RA and is also correlated with disease activity [20]. Since normalisation of the MMP-3 level is thought to reflect inhibition of excessive cartilage and bone destruction in the joints, normalisation of the MMP-3 level may indicate an improvement in the underlying cause of RA as well as synovial inflammation. In this study, we did not examine the progression of joint damage by imaging after restarting TCZ. However, since the MMP-3 levels were quickly improved after TCZ retreatment, TCZ retreatment should be considered to control disease activities and potentially prevent joint destruction once disease activity increased after the cessation of TCZ treatment. Further study of changes in radiological progression will be necessary to validate the modality of TCZ treatment investigated in the DREAM/RESTORE studies.

In conclusion, our results indicate that TCZ retreatment was effective and well tolerated in patients in whom disease activity recurred after cessation of TCZ monotherapy. Our

results also indicate that, together with the results of the DREAM study, the treatment interval of TCZ can also be adjusted flexibly without attenuation of efficacy.

Acknowledgments The authors wish to thank all members of the MRA study group for RA for treating the patients. This study was funded by Chugai Pharmaceutical Co. Ltd.

Conflict of interest N. Nishimoto has served as a consultant to and received honoraria from Chugai Pharmaceutical Co. Ltd. NN also works as a scientific advisor to F. Hoffmann-La Roche, which is developing TCZ in collaboration with Chugai Pharmaceutical Co. Ltd. NN also has received research grants from Chugai Pharmaceutical Co. Ltd., Bristol-Myers Japan, and Pfizer Japan Inc. K. Amano has received research grants from Chugai Pharmaceutical Co. Ltd., Astellas Pharm Inc., and Mitsubishi Tanabe Pharma. Y. Hirabayashi has received speakers' bureau honoraria from Chugai Pharmaceutical Co. Ltd. M. Iwamoto has received royalties from Chugai Pharmaceutical Co. Ltd. H. Kohsaka has received research grants, consultant fees, and/or speakers' bureau honoraria from Bristol-Myers Japan, Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. T. Mimura has received research grants from Abbott Japan, Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical Co. Ltd. T. Takeuchi has received research grants, consultant fees, and/or speakers' bureau honoraria from Abbott Japan, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma, Novartis, Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. S. Tohma has received a research grant from Pfizer Japan Inc. and has received subsidies or donations from the Health and Labour Sciences Research Grants for Research on Allergic Disease and Immunology and from Chugai Pharmaceutical Co. Ltd. N. Takagi is a full-time employee of Chugai Pharmaceutical Co. Ltd. All other authors have declared no conflicts of interest.

References

1. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin 6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthr Rheum. 2002;46:3143–50.
2. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30: 1426–35.
3. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr Rheum. 2004;50:1761–9.
4. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum. 2006;54:2817–29.
5. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
6. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.
7. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum. 2008;58:2968–80.
8. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.
9. Nishimoto N, Miyasaka N, Yamamoto K, et al. Relationship between serum IL-6 levels after tocilizumab treatment and clinical remission in active rheumatoid arthritis (RA) patients [abstract]. Ann Rheum Dis. 2008;67(Suppl 2):90.
10. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
11. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.
12. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum. 2011;63:609–21.
13. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2013. doi:10.1007/s10165-013-0894-z
14. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004;43:1252–5.
15. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–13.
16. Sagawa A. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study. Mod Rheumatol. 2011;21:352–8. doi:10.1007/s10165-011-0419-6.
17. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
18. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
19. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286–91.
20. Ribbens C, Andre B, Jaspar JM, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol. 2000;27: 888–93.

Biochemical and Biophysical Research Communications 448 (2014) 287–291

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

Allograft inflammatory factor-1 stimulates chemokine production and induces chemotaxis in human peripheral blood mononuclear cells

Masatoshi Kadoya [a], Aihiro Yamamoto [a], Masahide Hamaguchi [a], Hiroshi Obayashi [b], Katsura Mizushima [c], Mitsuhiro Ohta [d], Takahiro Seno [a,e], Ryo Oda [f], Hiroyoshi Fujiwara [f], Masataka Kohno [a], Yutaka Kawahito [a,*]

[a] Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
[b] Institute of Bio-Response Informatics, Kyoto, Japan
[c] Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
[d] Department of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Japan
[e] Department of Rheumatic Diseases and Joint Function, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
[f] Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

ARTICLE INFO

Article history:
Received 16 April 2014
Available online 4 May 2014

Keywords:
Allograft inflammatory factor-1
AIF-1
Chemotaxis
MIP-1α
IL-6

ABSTRACT

Allograft inflammatory factor-1 (AIF-1) is expressed by macrophages, fibroblasts, endothelial cells and smooth muscle cells in immune-inflammatory disorders such as systemic sclerosis, rheumatoid arthritis and several vasculopathies. However, its molecular function is not fully understood. In this study, we examined gene expression profiles and induction of chemokines in monocytes treated with recombinant human AIF (rhAIF-1). Using the high-density oligonucleotide microarray technique, we compared mRNA expression profiles of rhAIF-1-stimulated $CD14^+$ peripheral blood mononuclear cells ($CD14^+$ PBMCs) derived from healthy volunteers. We demonstrated upregulation of genes for several CC chemokines such as CCL1, CCL2, CCL3, CCL7, and CCL20. Next, using ELISAs, we confirmed that rhAIF-1 promoted the secretion of CCL3/MIP-1α and IL-6 by $CD14^+$ PBMCs, whereas only small amounts of CCL1, CCL2/MCP-1, CCL7/MCP-3 and CCL20/MIP-3α were secreted. Conditioned media from rhAIF-1stimulated $CD14^+$ PBMCs resulted in migration of PBMCs. These findings suggest that AIF-1, which induced chemokines and enhanced chemotaxis of monocytes, may represent a molecular target for the therapy of immune-inflammatory disorders.

1. Introduction

Allograft inflammatory factor-1 (AIF-1) is a cytokine that was originally identified and cloned from rat heart allogeneic grafts undergoing chronic transplant rejection [1]. AIF-1 is a 17 kDa, interferon γ-inducible, Ca^{2+}-binding EF-hand protein that is encoded within the major histocompatibility complex (MHC) class III genomic region [1–3]. AIF-1 is thought to be involved in the regulation of cell cycle progression and cellular activation status [4].

Previously, it was reported that AIF-1 was highly upregulated in various autoimmune diseases and inflammatory disorders such as psoriasis, lichen planus, and systemic sclerosis. The main cell types expressing AIF-1 in these affected skins are macrophages and Langerhans cells [5,6].

We recently showed that mice expressed AIF in infiltrating mononuclear cells and fibroblasts in thickened skin of scleroderma-tous graft-vs.-host disease (GVHD) and in synovial tissues in rheumatoid arthritis (RA). Recombinant human AIF-1 (rhAIF-1) induced the proliferation of cultured synovial cells and the migration and proliferation of dermal fibroblasts [7]. Moreover, in patients with RA, rhAIF-1 increased IL-6 production by synovial fibroblasts and peripheral blood monocytes (PBMCs) and by dermal fibroblasts [8]. In addition, AIF-1 plays a role in the activation of macrophages, T-lymphocytes and vascular smooth muscle cells (VSMCs), and endothelial cells that participate in atherogenesis and the vascular response to injury [4,9,10].

Chemokines are small, chemoattractant cytokines that play key roles in the accumulation of inflammatory cells at the site of inflammation. Therefore, chemokines and chemokine receptors are considered to be therapeutic targets in several chronic inflammatory disorders such as RA [11]. The relationship between AIF-1 and chemokines is not clear. Recently, microarray techniques have become available that allow characterization of the mRNA

* Corresponding author. Address: Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. Fax: +81 75 252 3721.
E-mail address: kawahity@koto.kpu-m.ac.jp (Y. Kawahito).

http://dx.doi.org/10.1016/j.bbrc.2014.04.106
0006-291X/

expression pattern of a large number of genes. In this study, using the GeneChip system for comprehensive analysis, we identified the specific gene expression profiles of $CD14^+$ peripheral blood mononuclear cells ($CD14^+$ PBMCs) stimulated by rhAIF-1. Then, we examined cytokine production by ELISAs and their functions by using cell migration assay.

2. Materials and methods

2.1. Preparation of recombinant human AIF-1 (rhAIF-1)

Human *AIF1* cDNA was amplified from human peripheral blood lymphocyte cDNA (BD Bioscience Clontech, Palo Alto, CA) using PCR. The forward and reverse primers were 5′-GTG GAT CCA TGA GCC AAA CCA GGG ATT T-3′ (containing a BamHI site) and 5′-CAC TCG AGT CAG ATA GGG CTT TCT TGG CT-3′ (containing a XhoI site). The DNA fragment obtained was inserted in the BamHI/XhoI sites of pGEX-4 (Amersham Biosciences, Piscataway, NJ) in frame. To express AIF-1 as a glutathione *S*-transferase fusion protein, the protein was purified with a glutathione-*S*-transferase purification system (Amersham Biosciences) and affinity chromatography with anti-rhAIF-$1_{113-129}$ antibody.

To investigate the effect of AIF-1 on chemotaxis and cytokine induction, rhAIF-1 was treated with Detoxi-Gel Endotoxin Removing Gel (Pierce, Rockford, IL, USA). Endotoxin detection was performed using *Limulus* amoebocyte lysate analysis (Wako Pure Chemical, Osaka, Japan) and treated AIF protein was confirmed to contain less than 0.1 ng/μg of endotoxin.

2.2. Preparation of anti-human AIF-1_{53-71} and AIF-$1_{113-129}$ antibodies

Two synthetic peptides that corresponded to residues 53–71 and 113–129 of human AIF-1 (AIF-1_{53-71} and AIF-$1_{113-129}$, respectively) as deduced from the nucleotide sequence of the human *AIF1* gene, were obtained with an additional cysteine residue at the N-terminus (Biologica, Nagoya, Japan). Following purification by reverse phase high-performance liquid chromatography, the synthetic peptide (purity > 90%) was coupled to keyhole limpet hemocyanin with *N*-(ε-maleimidocaproyloxy) succinimide (Sigma–Aldrich). The carrier-conjugated peptide was then emulsified with Freund's complete adjuvant (Difco Laboratories, Detroit, MI) and injected subcutaneously (0.5 mg/injection) into rabbits. The rabbits were immunized six times at ten day intervals. Blood samples were collected ten days after the last injection and the specific antibody in the sera was purified using an AIF-1 peptide-coupled cyanogen bromide-activated Sepharose affinity column. The antibodies reacted with proteins from abdominal adipose tissue and PBMCs that were identical in molecular size of purified recombinant human AIF-1.

2.3. Isolation and stimulation of $CD14^+$ PBMCs

PBMCs were isolated from healthy volunteers ($n = 5$; age: 34 ± 2) using Ficoll–Paque density gradients (GE Healthcare Bio-Sciences, Sweden). Human monocytes were purified from the cells using the MACS (Miltenyi Biotec, Germany) system, a direct magnetic labeling technique using anti-human CD14 microbeads (Miltenyi Biotec, Germany), according to the manufacturer's protocol (Daiichi Pure Chemicals Japan).

All subjects in this study provided written informed consent to participate. The study was approved by the Ethical Committee of Kyoto Prefectural University of Medicine (Kyoto, Japan).

2.4. Preparation of biotin-labeled complementary RNA (cRNA) and hybridization to microarrays

$CD14^+$ PBMCs were seeded in 92-mm dishes at a concentration of 2×10^5 cells/mL/dish in a volume of 10 mL of serum-free RPMI1640, then incubated with PBS or rhAIF-1 (100 ng/mL). After incubation at 37 °C in a humidified atmosphere of 5% CO_2/95% air for 24 h, total RNA was extracted using a Qiagen RNeasy kit (Qiagen, Valencia, CA, USA). Preparation of cRNA and target hybridization was performed according to the Affymetrix GeneChip® technical protocol (Affymetrix, Santa Clara, CA, USA). Briefly, double-stranded cDNA was prepared from 1 μg of total RNA using Life Technologies Superscript Choice system (Life Technologies, Inc., Gaithersburg, MD, USA) and an oligo-(dT) 24 anchored T7 primer. Biotinylated RNA was synthesized from the double-stranded cDNA by in vitro transcription using 3′-Amplification Reagents for IVT Labeling (Affymetrix kit). Transcription products were purified using a Qiagen RNeasy column (Qiagen). After biotinylation, the in vitro transcription products were fragmented for 35 min at 94 °C in a buffer composed of 200 mmol/L Tris acetate (pH 8.1), 500 mmol/L potassium acetate and 150 mmol/L magnesium acetate. Human Genome® U133 plus 2.0 (Affymetrix, Santa Clara, CA, USA) was hybridized with the biotinylated products (0.05 μg/μL per chip) for 16 h at 45 °C using the manufacturer's hybridization buffer. After washing the arrays, the hybridized RNA was detected by staining with streptavidin–phycoerythrin SSPE, 0.01% Tween-20, pH 7.6, 2 mg/mL acetylated BSA and 10 mg/mL streptavidin–phycoerythrin (Molecular Probes, Carlsbad, CA, USA). Microarrays were scanned using a specially designed confocal scanner (GeneChip® Scanner 7G; Affymetrix).

2.5. Induction of IL-6, CCL1, CCL2/MCP-1, CCL3/MIP-1α, CCL7/MCP-3, and CCL20 /MIP-3α, and production by $CD14^+$ PBMCs by rhAIF-1

$CD14^+$ PBMCs from healthy volunteers ($n = 5$) were incubated with serum-free RPMI-1640 medium (Nissui Pharmaceutical) containing zero, one, ten, or 100 ng/mL of rhAIF-1 or 10 ng/mL of LPS from *Escherichia coli* (Sigma–Aldrich, MO, USA). After incubation at 37 °C in a humidified atmosphere of 5% CO_2/95% air for 24 h, the culture supernatants were recovered and stored at −80 °C until assay. IL-6, CCL1, CCL2/MCP-1, CCL3/MIP-1α, CCL7/MCP-3 and CCL20/MIP-3α concentrations were measured using commercial ELISA kits (IL-6 and CCL2/MCP-1: eBioscience CA USA) (CCL1: Antigenix America Inc., NY, USA) (CCL3/MIP-1a, CCL7/MCP-3, and CCL20/MIP-3α: R&D systems, MN, USA) according to the manufacturer's instructions. The absorbance was measured with a microplate reader (MPRA4, TOSHO, Tokyo, Japan).

3. Cell migration assays

We prepared culture supernatants of $CD14^+$ PBMCs (1×10^6/mL, $n = 6$) that had been incubated with serum-free RPMI-1640 medium (Nissui Pharmaceutical) with or without of 1, 10, or 100 ng/mL rhAIF-1. After incubation at 37 °C in a humidified atmosphere of 5% CO_2/95% air for 12 h, the culture supernatants were harvested, stored at −80 °C, and used as lower chamber liquids. Then, we examined human PBMC migration induced by the culture supernatants using cell culture inserts and (Control Cell Culture Inserts in two 24-well plates, pore size 3.0 μm, BD Bioscience, USA). Human PBMC suspensions (5×10^6 cells/mL) were placed in the upper chamber ($n = 6$). Culture supernatants (400 μL) were added to lower chambers filled with the culture supernatants as mentioned above or CCL3/MIP-1α (50 ng/mL) in serum-free RPMI-1640 medium. The chambers were placed in a 37 °C humidified atmosphere of 5% CO_2 in air for 90 min. Migratory PBMCs

extended protrusions towards chemoattractants and ultimately passed through the pores of the polycarbonate membrane. We assessed chemotactic response both by counting the number of migratory PBMCs under the optical microscope and by Chemotactic Index which was calculated by dividing the number of migrated cells in each chamber by that in the chamber added CCL3/MIP-1α (50 ng/mL).

3.1. Statistical analysis

Array data analysis was carried out using Affymetrix GeneChip Operating Software (GCOS) version 1.4. GCOS analyzed image data and computed an intensity value for each probe cell. Briefly, mismatched probes acted as specificity controls that allowed the direct subtraction of both background and cross-hybridization signals. To quantitatively determine RNA abundance, the average difference values (i.e., gene expression levels) representing the perfect match–mismatch for each gene-specific probe family was calculated and the fold-changes in average difference values were determined according to Affymetrix algorithms and procedures. Hierarchical clustering analysis of the gene expression profiles of 118 genes was performed using GeneSpring software 7.3.1 (Agilent Technologies, Inc., Santa Clara, CA, USA). The differences were analyzed by Wilcoxon signed-rank test in ELISA and by Mann–Whitney U and Kruskal–Wallis tests in Cell migration assay.

4. Results

4.1. Upregulated genes following stimulation of CD14$^+$ PBMC by rhAIF-1

We compared mRNA expression profiles of monocytes with and without rhAIF-1 stimulation, using CD14$^+$ PBMCs derived from five healthy volunteers. We used the Human Genome U133 plus 2.0 array (Affymetrix), which contained about 55,000 probes. Comparison of the gene expression levels from vehicle- and rhAIF-1-treated CD14$^+$ PBMCs enabled the identification of 10^5 genes demonstrating greater than twofold alterations after AIF-1 stimulation. Using hierarchical clustering analysis of the gene expression profiles, we narrowed the expression of genes to 56 gene probe sets in terms of "inflammatory diseases". That probe set contained several chemokines. They included major CC chemokine genes such as *CCL1*, *CCL2/MCP-1*, *CCL3/MIP-1α*, *CCL7/MCP-3* and *CCL20/MIP-3α*. Among them, *CCL2/MCP-1*, *CCL7/MCP-3* and *CCL20/MIP-3α* genes were strongly upregulated after rhAIF-1 stimulation (Fig. 1).



Fig. 1. Gene cluster analysis of peripheral blood CD14$^+$ mononuclear cells with and without rhAIF-1 stimulation. Starting with CD14$^+$ PBMCs stimulated by rhAIF-1 (100 ng/mL), we used hierarchical clustering analysis of the gene expression profiles of approximately 10,000 genes. We identified the expression of 58 genes associated with "proinflammatory cytokines" (at left). The data were analyzed by applying a hierarchical-tree algorithm to the normalized intensities. Upregulated genes are indicated by red shades and repressed genes by green. For one example, we picked up a region where gene expression was increased strongly after rhAIF-1 stimulation (at right). Among them, genes for CC chemokines such as CCL2/MCP-1, CCL3/MIP-1α and CCL7/MCP-3 were included in the region.

4.2. IL-6 and chemokine secretion from CD14⁺ PBMCs after rhAIF-1 stimulation

From the results of the mRNA expression profiles of CD14⁺ PBMCs stimulated by rhAIF-1 ($n = 5$), we examined the expression of IL-6, CCL1, CCL2/MCP-1, CCL3/MIP-1α, CCL7/MCP-3 and CCL20/MIP-3α proteins following rhAIF-1-stimulation. As shown in Fig. 2, the concentrations of IL-6 and CCL3/MIP-1α in the culture supernatant significantly increased after stimulation by human rAIF-1 for 24 h ($P < 0.05$). Expression of CCL1, CCL2/MCP-1, CCL7/MCP-3 and CCL20 /MIP-3 increased a very small amount (data not shown).

4.3. PBMC migration induced by cultured media from rhAIF-1-stimulated CD14⁺ PBMCs

CD14⁺ PBMCs were stimulated with rhAIF-1 (zero, one, ten, or 100 ng/mL) in RPMI, for 12 h. The supernatants were collected and used for cell migration assays. PBMCs ($n = 6$) were cultured for 90 min, and were attracted by the rhAIF-1-stimulated culture supernatant. The migrated cell counts were increased by culture supernatants from CD14⁺ PBMCs stimulated with 100 ng/mL rhAIF-1 compared to RPMI ($P < 0.05$, Fig. 3). There was no significant difference in the number of the migratory cells between 100 ng/mL rhAIF-1 and 50 ng/mL CCL3/MIP-1α as reference control. We confirmed that culture supernatants from rhAIF-1 stimulated CD14⁺ PBMCs induced the chemotaxis of PBMCs (Table 1).

5. Discussion

In this study, we used a high density oligonucleotide microarray technique for mRNA expression profiling of CD14⁺ PBMCs to investigate the cellular response of PBMCs to rhAIF-1 stimulation. We identified upregulated expression of several CC chemokine and cytokine genes. They included CC chemokine genes such as *CCL1*, *CCL2/MCP-1*, *CCL3/MIP-1α*, *CCL7/MCP-3* and *CCL20/MIP-3α*. Then, we used ELISAs to confirm that rhAIF-1 promoted the secretion of CCL3/MIP-1α and IL-6 by CD14⁺ PBMCs. However, secretions of CCL1, CCL2/MCP-1, CCL7/MCP-3 and CCL20/MIP-3α were at very low levels. Finally, we demonstrated that the cultured media from rhAIF-1-stimulated CD14⁺ PBMCs enhanced migration of PBMCs.



Fig. 2. Induction of IL-6 (A) and CCL3/MIP-1α (B) secretion from CD14⁺ PBMC stimulated by rhAIF-1. Human CD14⁺ PBMC ($n = 5$) were stimulated with serum-free RPMI-1640 medium containing 0, 1, 10 or 100 ng/mL rhAIF-1 or 10 ng/mL of LPS. Concentrations of IL-6 and CCL3 in the supernatant were measured with an ELISA at 24 h. Each bar represents the mean ± SE. The difference was analyzed by Wilcoxon signed-rank test. (*$P < 0.05$). NC: negative control.



Fig. 3. PBMC migration was stimulated by culture supernatants from cells treated with rhAIF-1. Culture supernatants were prepared from human CD14⁺ PBMC ($n = 6$) that had been incubated with serum-free RPMI-1640 medium with or without of 1, 10, or 100 ng/mL rhAIF-1 for 12 h. These culture supernatants or 50 ng/mL CCL3 were added to lower chambers, and PBMCs were applied to the surface of the polycarbonate membranes at 5×10^6 cells/mL. Cell migration into the lower chamber significantly increased with culture supernatants from human CD14⁺ PBMC stimulated with 100 ng/mL of rhAIF-1 for 90 min. The difference was analyzed by Mann–Whitney U and Kruskal–Wallis tests in Cell migration assay (*$P < 0.05$). The Y-axis indicates the number of cells that migrated into the lower chamber (A) and Chemotactic Index (B). On each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles. There was no significant difference in the number of the migratory cells between 100 ng/mL rhAIF-1 and 50 ng/mL CCL3/MIP-1α as reference control. NC (normal control) indicates culture supernatants incubated with serum-free RPMI-1640 medium containing no rhAIF-1. #The index of NC is 1.0. The other medians were calculated as the ratio on the basis of NC.